Atlas Trials

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Clinical trial NCT04516161 · COMPLETED

Trial details

NCT number
NCT04516161
Sponsor
Bayer
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Start date
2020-08-03
Primary completion
2021-03-31
Enrollment
1180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.